Motpoly XR (Lacosamide) Patent Expiration, LOE Window & CMS Spending

Motpoly XR (Lacosamide) by Aucta: FDA Orange Book LOE 2040-06-05, 12 AB generics, $965K 2024 CMS Part D & Medicaid spend, and $1,250 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAucta
FDA Application & PathwayN216185 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-06-05
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$965K
2024 Medicare Part D Spend$394K
2024 Medicaid Spend$571K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,250 intro WAC)